Pharmacodynamics
garadacimab
BLOOD
Blood samples were collected before dosing and at 30 min and 6 h after dosing on Day 1, and Days 2, 7, 14, 21 and 28. Samples were analysed from the safety analysis population by the central laboratory using validated methods.For both the garadacimab and placebo groups pharmacodynamic biomarkers (activated partial thromboplastin time [aPTT], FXII levels and FXIIa-mediated kallikrein activity [FXIIa-mKA] measured to assess target activation), were evaluated as exploratory biomarkers. Further coagulation biomarkers including prothrombin time/international normalised ratio and D-dimer were also assessed.